Guangzhou Beishi Pharmaceutical

Beishi Pharma is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the development of Tumor-Infiltrating Lymphocyte (TIL) therapies for solid tumors. The company's lead candidate, BST02, is an autologous TIL therapy that has achieved the milestone of being the first TIL product in China to receive IND approval for cervical cancer. Beishi Pharma leverages proprietary technology to optimize the expansion and fitness of TILs, aiming to overcome the limitations of traditional cell therapies in treating epithelial cancers. The firm is led by experts in immunology and is supported by major Chinese venture capital investors.